Claudins as prognostic factors for renal cell cancer

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 4181-4188

  Virman, Juha Pekka ^a   Soini, Ylermi ^b   Kujala, Paula ^c   Luukkaala, Tiina ^d   Salminen, Tapio ^c   Sunela, Kaisa ^c   Kellokumpu Lehtinen, Pirkko Liisa ^a,c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d PIRKANMAA HOSPITAL DISTRICT   (Finland)

Author keywords

Claudins; Expression; Prognostic factors; Renal cell cancer (RCC)

Indexed keywords

CLAUDIN 1; CLAUDIN 2; CLAUDIN 3; CLAUDIN 4; CLAUDIN 5; CLAUDIN 7; CLAUDIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MALE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL TIME; CHEMISTRY; EXPRESSION; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROGNOSTIC FACTORS; RENAL CELL CANCER (RCC);

CLAUDINS; EXPRESSION; PROGNOSTIC FACTORS; RENAL CELL CANCER (RCC);

AGED; CARCINOMA, RENAL CELL; CLAUDINS; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 84908682178     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Mejéan A, Oudard S and Thiounn N: Prognostic factors of renal cell carcinoma. J Urol 169: 821-827, 2003.
2. Kallio JP, Hirvikoski P, Helin H, Luukkaala T, Tammela TL, Kellokumpu-Lehtinen P and Martikainen PM: Renal cell carcinoma Mib-1, Bax and Bcl-2 expression, and prognosis. J Urol 172: 2158-2161, 2004.
3. Cheville JC, Zincke H, Lohse CM, Sebo TJ, Riehle D, Weaver AL and Blute M: pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival. Cancer 94: 2180-2184, 2002.
4. Paradis V, Lagha NB, Zeimoura L, Blanchet P, Eschwege P, Ba N, Benoît G, Jardin A and Bedossa P: Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Archiv 436: 351-356, 2000.
5. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G and Ljundberg B: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. Br J Urol Int 93: 297-302, 2004.
6. Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T and Chiba H: Tight junctions and human diseases. Med Elect Microsc 36: 147-156, 2003.
7. Lee DBN, Huang E and Ward HJ: Tight junction biology and kidney dysfunction. Am J Physiol Renal Physiol 290: 20-34, 2006.
8. Gonzalez-Mariscal L, Betanzos A, Nava P and Jaramillo BE: Tight junction proteins. Progress in Biophysics & Molecular Biology 81: 1-44, 2003.
9. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65: 9603-9606, 2005.
10. Kolokytha P, Yiannou P, Keramopoulos D, Kolokythas A, Nonni A, Patsouris E and Pavlakis K: Claudin-3 and Claudin-4: Distinct prognostic significance in triple-negative and luminal breast cancer. Appl Immunohistochem Mol Morphol 22: 125-131, 2014.
11. Soini Y: Claudins 2, 3, 4 and 5 in Paget's disease and breast carcinoma. Human Pathol 35: 1531-1536, 2004.
12. Soini Y, Kinnula V, Kahlos K and Pääkkö P: Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol 59: 250-254, 2006.
13. De Aquino AR, De Carvalho CH, Nonaka CF, Freitas R de A,de Souza LB and Pinto LP: Immunoexpression of claudin-1 and Nm23-H1 in metastatic and nonmetastatic lower lip squamous-cell carcinoma. Appl Immunohistochem Mol Morphol 20: 595-601, 2012.
14. Soini Y. Tommola S. Helin H and Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virch Archiv 448: 52-58, 2006.
15. Soini Y: Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 46: 551-560, 2005.
16. Li L, Yao J, Di Sant'Agnese PA, Bourne PA, Picken MM, Young AN, Shen SS and Huang J: Expression of claudin-7 in benign kidney and kidney tumors. Int J Clin Exp Pathol 1: 57-64, 2007.
17. Lechpammer M, Resnick M, Sabo E, Yakirevich E, Greaves WO, Sciandra KT, Tavares R, Noble LC, DeLellis RA and Wang LJ: The diagnostic and prognostic utility of claudin expression in renal cell neoplasms. Mod Pathol 21: 1320-1329, 2008.
18. Fritzsche F, Oelrich B, Johannsen M, Kristiansen I, Moch H, Jung K and Kristiansen G: Claudin-1 protein expression is a prognostic marker of patient survival in renal cell carcinomas. Clin Cancer Res 14: 7035-7041, 2008.
19. Sobin LH and Wittekind CH: TNM Classification of Malignant Tumours. 6th ed. Hoboken NJ: John Wiley & Sons: Renal cell carcinoma staging (TNM), 2002.
20. Kovacs G, Akhtar M, Beckwith BJ, Buqert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljundberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Sriqley JR, Störkel S, van der Berg E and Zbar B: The Heidelberg classification of renal cell tumours. J Pathol 183: 131-133, 1997.
21. Fuhrman S, Lasky L and Limas C: Prognostic significance of morphologic parametres in renal cell carcinoma. AM J Surg Pathology 6: 665, 1982.
22. Coutinho-Camillo CM, Lourenco SV, Da Fonseca FP and Soares FA: Claudin expression is dysregulated in prostate adenocarcinomas but does not correlate with main clinicopathological parameters. Pathology 43: 143-148, 2011.
23. Sheehan GM, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RB Jr and Ross JS: Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognosis variables in prostatic carcinomas. Human Pathol 38: 564-569, 2007.
24. Pan XY, Wang B, Che YC, Wenq ZP, Dai HY and Penq W: Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue. Int J Gyn Cancer 17: 233-241, 2007.
25. Reyes JL, Lamas M, Martin D, del Carmen Namorado M, Islas S, Luna J, Tauc M and González-Mariscal L: The renal segmental distribution of claudins changes with development. Kidney Int 62: 476-487, 2002.
26. Sunela KL, Kataja MJ and Kellokumpu-Lehtinen P-L: Influence of body mass index and smoking on the long-term survival of patients with renal cell cancer. Clin Genitourin Cancer 11: 258-264, 2013.
27. Sunela KL, Lehtinen ET, Kataja MJ, Kujala PM, Soimakallio S and Kellokumpu-Lehtinen PL: Development of renal cell carcinoma (RCC) diagnostic and impact on prognosis. Br J Urol Int 113: 228-235, 2014.
28. Vaishampayan U, Vankayla H, Vigneau FD, Quarshie W, Dickow B, Chalasani S and Schwartz K: The effect of targeted therapy on overall survival in advanced renal cancer: A study of the national surveillance epidemiology and end results registry database. Clin Genitourin Cancer 12: 124-129, 2014.
29. Twardowski PW, Mack PC and Lara PM: Papillary renal cell carcinoma: Current progress and future directions. Clin Genitourin Cancer 12: 74-79, 2014.
30. Sauer T, Pedersen MK, Ebeltoft K and Naess O: Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology 16: 193-198, 2005.
31. Takala H, Saarnio J, Wiik H and Soini Y: Claudins 1, 3, 4, 5 and 7 in esophageal cancer: loss of claudin 3 and 4 expression is associated with metastatic behavior. Apmis 115: 838-847, 2007.